Basilea Pharmaceutica AG

Basilea Pharmaceutica AGverified

BPMUF

Price:

$52.83

Market Cap:

$553.48M

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus a...[Read more]

Industry

Biotechnology

IPO Date

2015-06-09

Stock Exchange

PNK

Ticker

BPMUF

The Enterprise Value as of November 2024 (TTM) for Basilea Pharmaceutica AG (BPMUF) is 596.45M

According to Basilea Pharmaceutica AG’s latest financial reports and current stock price. The company's current Enterprise Value is 596.45M. This represents a change of 44.65% compared to the average of 412.34M of the last 4 quarters.

Basilea Pharmaceutica AG (BPMUF) Historical Enterprise Value (quarterly & annually)

How has BPMUF Enterprise Value performed in the past?

The mean historical Enterprise Value of Basilea Pharmaceutica AG over the last ten years is 734.35M. The current 596.45M Enterprise Value has changed 8.02% with respect to the historical average. Over the past ten years (40 quarters), BPMUF's Enterprise Value was at its highest in in the December 2014 quarter at 1.18B. The Enterprise Value was at its lowest in in the March 2024 quarter at 0.

Quarterly (TTM)
Annual

Average

734.35M

Median

680.71M

Minimum

482.06M

Maximum

1.17B

Basilea Pharmaceutica AG (BPMUF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Basilea Pharmaceutica AG Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 40.15%

Maximum Annual Enterprise Value = 1.17B

Minimum Annual Increase = -40.02%

Minimum Annual Enterprise Value = 482.06M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023482.06M-28.31%
2022672.43M11.72%
2021601.91M-17.66%
2020731.02M20.68%
2019605.73M4.58%
2018579.22M-40.02%
2017965.63M40.15%
2016688.99M-18.67%
2015847.19M-27.55%
20141.17B12.46%

Basilea Pharmaceutica AG (BPMUF) Average Enterprise Value

How has BPMUF Enterprise Value performed in the past?

The current Enterprise Value of Basilea Pharmaceutica AG (BPMUF) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

585.47M

5-year avg

618.63M

10-year avg

734.35M

Basilea Pharmaceutica AG (BPMUF) Enterprise Value vs. Peers

How is BPMUF’s Enterprise Value compared to its peers?

Basilea Pharmaceutica AG’s Enterprise Value is greater than Ocuphire Pharma, Inc. (-9671816.00), greater than Reviva Pharmaceuticals Holdings, Inc. (28.64M), greater than Protalix BioTherapeutics, Inc. (96.89M), less than EyePoint Pharmaceuticals, Inc. (707.60M), greater than SELLAS Life Sciences Group, Inc. (66.71M), greater than ProQR Therapeutics N.V. (283.06M), less than Alnylam Pharmaceuticals, Inc. (35.02B), less than Wave Life Sciences Ltd. (2.01B), less than Blueprint Medicines Corporation (6.13B), less than Apellis Pharmaceuticals, Inc. (3.59B), less than Moderna, Inc. (0), less than CureVac N.V. (18.10B), greater than Novavax, Inc. (395.26M), less than CohBar, Inc. (1.00B), greater than Reata Pharmaceuticals, Inc. (-4506335.00), less than BioNTech SE (6.68B), less than Ginkgo Bioworks Holdings, Inc. (13.69B), greater than CRISPR Therapeutics AG (143.59M), less than null (4.06B),

Build a custom stock screener for Basilea Pharmaceutica AG (BPMUF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Basilea Pharmaceutica AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Basilea Pharmaceutica AG (BPMUF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Basilea Pharmaceutica AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Basilea Pharmaceutica AG's Enterprise Value?

What is the highest Enterprise Value for Basilea Pharmaceutica AG (BPMUF)?

What is the 3-year average Enterprise Value for Basilea Pharmaceutica AG (BPMUF)?

What is the 5-year average Enterprise Value for Basilea Pharmaceutica AG (BPMUF)?

How does the current Enterprise Value for Basilea Pharmaceutica AG (BPMUF) compare to its historical average?